Investigational Drug Information for Lapaquistat
✉ Email this page to a colleague
What is the development status for investigational drug Lapaquistat?
Lapaquistat is an investigational drug.
There have been 16 clinical trials for Lapaquistat.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2005.
The most common disease conditions in clinical trials are Hypercholesterolemia, Dyslipidemias, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda and [disabled in preview].
Summary for Lapaquistat
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 107 |
| WIPO Patent Applications | 70 |
| Japanese Patent Applications | 18 |
| Clinical Trial Progress | Phase 3 (2005-10-01) |
| Vendors | 26 |
Recent Clinical Trials for Lapaquistat
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia | Takeda | Phase 3 |
| Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia | Takeda | Phase 3 |
| Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia | Takeda | Phase 2 |
Clinical Trial Summary for Lapaquistat
Top disease conditions for Lapaquistat
Top clinical trial sponsors for Lapaquistat
US Patents for Lapaquistat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
